Progress of small molecules for targeted protein degradation: PROTACs and other technologies
HY Zhao, M Xin, SQ Zhang - Drug Development Research, 2023 - Wiley Online Library
Recent years have witnessed the rapid development of targeted protein degradation (TPD),
especially proteolysis targeting chimeras. These degraders have manifested many …
especially proteolysis targeting chimeras. These degraders have manifested many …
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews
V Georgoulis, AB Haidich, KI Bougioukas… - Critical Reviews in …, 2022 - Elsevier
In this overview we present a summary of evidence from systematic reviews (SRs) on the
safety and efficacy of carfilzomib in multiple myeloma (MM). Our search in electronic …
safety and efficacy of carfilzomib in multiple myeloma (MM). Our search in electronic …
Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis
K Suzuki, Y Shimazu, D Minakata, T Ikeda… - … and Cellular Therapy, 2023 - Elsevier
Autologous stem cell transplantation (ASCT) is the standard of care for myeloma patients
who achieve partial response (PR) or better after induction therapy. However, its clinical …
who achieve partial response (PR) or better after induction therapy. However, its clinical …
[HTML][HTML] How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
F de Arriba de la Fuente, C Montes Gaisán… - Cancers, 2023 - mdpi.com
Although lenalidomide-based combinations, such as lenalidomide plus a proteasome
inhibitor or an anti-CD38 monoclonal antibody, improve the overall response rate …
inhibitor or an anti-CD38 monoclonal antibody, improve the overall response rate …